Christian Hein’s Post

In "AI-readiness requires healthy tech" Patrick Herde from ModMed makes some strong arguments for considering the big picture and the long view as it relates to implementing AI in medical practices. The foundation, as it is with building a house, remains critical. He writes "As AI continues to dominate healthcare conversations, it is tempting to see it as a silver bullet. But before jumping in, practices must assess their current technology stack." Well put, Patrick! At Sophrona Solutions, Inc. this principle applies too. True innovation in our operations requires assessment of process, the existing systems and tools we have, and how effectively we have codified institutional knowledge in our internal ops technology stack. Doing this will make all the difference in what fruits we can reap from AI process innovation.

Agentic AI is reshaping how biopharma operates from R&D to commercialization. BCG and McKinsey show how AI agents can automate complex work, speed development, and lift productivity. Worth a read on where the industry is heading. 🔗 BCG 🔗 McKinsey

🚀 Excited to Share What’s Next for AI in MLR I’m thrilled to join John Oxley from Veeva Systems at the upcoming EU Veeva Summit next week to discuss how AI is transforming the MLR landscape — not as a distant vision, but as something happening right now. We’ll explore how thoughtful integration of AI can enhance collaboration, improve quality, and streamline the review process — all while keeping people and purpose at the center. This conversation is especially close to my heart, as it reflects years of imagining what “machine-assisted review” could look like — and seeing that vision start to take shape. If you’re attending the Summit, I hope you’ll join our session to hear how innovation, process, and human insight come together to shape the future of MLR. #VeevaSummit #DigitalInnovation #LifeSciences #MLRTransformation

The EU AI Act is more than legislation, it's a roadmap for responsible AI in pharma and life sciences. With high-risk applications under scrutiny, companies must rethink data governance, algorithmic transparency, and human oversight to stay compliant and competitive. Understanding these requirements early is critical to integrating AI safely and strategically into core business and clinical operations. In a new blog post by Tim Taylor, Sanjeev Jha, and Dorcas Eden, we break down the EU AI Act and provide actionable guidance for pharma companies preparing for this landmark regulatory shift, turning compliance into a competitive advantage. ➡️ https://hubs.li/Q03QpwYP0 #EUAIAct #AIinHealthcare #AIinPharma #MarketResearch C Space | Hall & Partners

Regulation rarely hands you a playbook, this one does. If we embed transparency, bias testing, and role-based oversight now, AI can move from pilots to production safely. Excellent walkthrough from the team on what to do first and how to stay ahead. https://hubs.li/Q03QpwYP0 #EUAIAct #AIinHealthcare #AIinPharma #MarketResearch #Insights

What does the EU AI Act mean for healthcare? My Escalent colleagues outline five steps pharma companies should take now to prepare for this landmark regulatory shift.

🔬 “The future of biotech depends on bringing discovery and development closer together.” Axendia, Inc. shares big topics from #Benchtalk, including how AI, automation, and data connectivity are redefining the scientific lifecycle across discovery, development, and GxP-regulated environments. 📖 Read the event brief: https://lnkd.in/eBSF86C9

AI is no longer just a buzzword in BioPharma—it’s a game changer. Recent insights show that 69% of the BioPharma industry is actively leveraging AI, and that number surprised me. I always knew AI was a nitro boost for accelerating research and drug discovery, but I didn’t realize it had become such a dominant force across the entire value chain. From predictive analytics in clinical trials to optimizing supply chains and personalizing patient care, AI isn’t just supporting innovation—it’s redefining it. The scale of adoption signals a clear message: AI is not optional; it’s foundational for the future of healthcare and life sciences.

It was great to attend the Science for Lunch event hosted by Medidata Solutions yesterday at the Medicon Village! The session was an inspiring reminder of how technology and AI are becoming powerful enablers in accelerating clinical research. One of the biggest takeaways for me was hearing how major regulatory agencies are not just open to, but actively encouraging, the use of technologies like AI to drive innovation responsibly. In summary — ➡️ Regulations are not a barrier, but a roadmap ➡️ AI governance is non-negotiable ➡️ Technology is the key to proactive compliance It’s exciting to see how the industry is moving from caution to confidence — embracing innovation while keeping patient safety and data integrity at the center. #ClinicalResearch #AI #Medidata #LifeSciences #Innovation #DigitalTransformation #RegulatoryScience